



GLAND PHARMA LIMITED

August 9, 2023

BSE Limited
Surveillance Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Clarification regarding increase in volumes- your e-mail dated August 9, 2023

Ref. No. L/SURV/ONL/PV/NP/2023-24/235

This is in reference to your e-mail dated 9th August, 2023 seeking clarification on significant increase in the volume of the shares across the Stock Exchanges, in the recent past.

In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI (LODR) Regulations, 2015), the Company has promptly intimated to the Stock Exchanges of all events and information that may have a probable bearing on the operation / performance of the Company including all price sensitive information, as and when required from time to time.

The Company disclosed the Financial Results (Limited Reviewed) for the quarter ended June 30, 2023 on August 7, 2023 and has filed the Annual Report, Notice of the Annual General Meeting and the Business Responsibility and Sustainability Report on August 8, 2023.

The Company do not have any undisclosed / potentially price sensitive information / event / announcement to be shared with the Stock Exchanges under Regulation 30 of SEBI (LODR) Regulations, 2015.

Please take the same on record.

Yours truly,
For Gland Pharma Limited

P Sampath Kumar
Company Secretary and Compliance Officer